Seroatlas · Human Serome Atlas

ITGB3

Integrin beta-3

Also known as: CD61, GP3A, GPIIIa, ITB3_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P05106
Gene
ITGB3
Ensembl
ENSG00000259207
Chromosome
17
Canonical length
788 aa
Protein class
Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins
Subcellular location
Nucleoplasm,Plasma membrane
Secretome location
Intracellular and membrane

OverviewNCBI Gene

The ITGB3 protein product is the integrin beta chain beta 3. Integrins are integral cell-surface proteins composed of an alpha chain and a beta chain. A given chain may combine with multiple partners resulting in different integrins. Integrin beta 3 is found along with the alpha IIb chain in platelets. Integrins are known to participate in cell adhesion as well as cell-surface mediated signalling. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

788 residues, UniProt reviewed canonical sequence.

>P05106|ITGB3
     1  MRARPRPRPL WATVLALGAL AGVGVGGPNI CTTRGVSSCQ QCLAVSPMCA WCSDEALPLG
    61  SPRCDLKENL LKDNCAPESI EFPVSEARVL EDRPLSDKGS GDSSQVTQVS PQRIALRLRP
   121  DDSKNFSIQV RQVEDYPVDI YYLMDLSYSM KDDLWSIQNL GTKLATQMRK LTSNLRIGFG
   181  AFVDKPVSPY MYISPPEALE NPCYDMKTTC LPMFGYKHVL TLTDQVTRFN EEVKKQSVSR
   241  NRDAPEGGFD AIMQATVCDE KIGWRNDASH LLVFTTDAKT HIALDGRLAG IVQPNDGQCH
   301  VGSDNHYSAS TTMDYPSLGL MTEKLSQKNI NLIFAVTENV VNLYQNYSEL IPGTTVGVLS
   361  MDSSNVLQLI VDAYGKIRSK VELEVRDLPE ELSLSFNATC LNNEVIPGLK SCMGLKIGDT
   421  VSFSIEAKVR GCPQEKEKSF TIKPVGFKDS LIVQVTFDCD CACQAQAEPN SHRCNNGNGT
   481  FECGVCRCGP GWLGSQCECS EEDYRPSQQD ECSPREGQPV CSQRGECLCG QCVCHSSDFG
   541  KITGKYCECD DFSCVRYKGE MCSGHGQCSC GDCLCDSDWT GYYCNCTTRT DTCMSSNGLL
   601  CSGRGKCECG SCVCIQPGSY GDTCEKCPTC PDACTFKKEC VECKKFDRGA LHDENTCNRY
   661  CRDEIESVKE LKDTGKDAVN CTYKNEDDCV VRFQYYEDSS GKSILYVVEE PECPKGPDIL
   721  VVLLSVMGAI LLIGLAALLI WKLLITIHDR KEFAKFEEER ARAKWDTANN PLYKEATSTF
   781  TNITYRGT

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ITGB3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.31
Highest tissue expression
53 nTPM

Expression across tissuesHPA

Tissue

  • thyroid gland: 53 nTPM
  • blood vessel: 38 nTPM
  • smooth muscle: 22 nTPM
  • colon: 21 nTPM
  • kidney: 16 nTPM
  • seminal vesicle: 16 nTPM

Single-cell type

  • platelets: 76 nCPM
  • late spermatids: 11 nCPM
  • megakaryocyte progenitors: 2.5 nCPM
  • early spermatids: 2.3 nCPM
  • vascular smooth muscle cells: 0.6 nCPM
  • undifferentiated spermatogonia: 0.4 nCPM

Immune cell

  • total PBMC: 6.9 nTPM
  • basophil: 5.6 nTPM
  • neutrophil: 3 nTPM
  • classical monocyte: 0.2 nTPM
  • eosinophil: 0.2 nTPM
  • naive B-cell: 0.2 nTPM

Brain region

  • medulla oblongata: 7.6 nTPM
  • thalamus: 5.2 nTPM
  • white matter: 4.8 nTPM
  • cerebral cortex: 4.7 nTPM
  • pons: 4.7 nTPM
  • midbrain: 4.4 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about ITGB3.

Disease | AllUniProt

Conditions ITGB3 is implicated in, by any mechanism.

  • Fetomaternal alloimmune thrombocytopenia 1 (FMAIT1) MIM:621264
  • Glanzmann thrombasthenia 2 (GT2) MIM:619267
  • Bleeding disorder, platelet-type, 24 (BDPLT24) MIM:619271

Disease | GeneticClinVar

192 pathogenic / likely-pathogenic of 971 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Disease | ImmuneIEDB

Conditions an epitope on ITGB3 was assayed in.

ReferencesPubMed · IEDB

Publications for ITGB3 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Reference: AutoantibodyPubMed

2 publications

Reference: T cellIEDB

5 publications

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.52
gnomAD pLI
0
gnomAD missense Z
1.16
DepMap mean gene effect
-0.04
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of ITGB3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ITGB3 as an antibody target. Whether an autoantibody or antibody against ITGB3 could matter depends on whether native ITGB3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ITGB3 is annotated at the cell surface, where native ITGB3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label ITGB3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/ITGB3. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...